Cellular processing of platinum anticancer drugs

[1]  S. Chaney,et al.  Protein interactions with platinum-DNA adducts: from structure to function. , 2004, Journal of inorganic biochemistry.

[2]  G. Samimi,et al.  The Copper Influx Transporter Human Copper Transport Protein 1 Regulates the Uptake of Cisplatin in Human Ovarian Carcinoma Cells , 2004, Molecular Pharmacology.

[3]  Takao Ohtsuka,et al.  The negative role of cyclin G in ATM-dependent p53 activation , 2004, Oncogene.

[4]  R. Day,et al.  Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines , 2004, International journal of cancer.

[5]  Kazuhiro Takahashi,et al.  Inhibition of NFκB Increases the Efficacy of Cisplatin in in Vitro and in Vivo Ovarian Cancer Models* , 2004, Journal of Biological Chemistry.

[6]  F. Yuan,et al.  Evidence for Involvement of HMGB1 Protein in Human DNA Mismatch Repair* , 2004, Journal of Biological Chemistry.

[7]  Dong Wang,et al.  Cisplatin-induced Post-translational Modification of Histones H3 and H4* , 2004, Journal of Biological Chemistry.

[8]  K. Ogawa,et al.  Prognostic Value of the Cu-Transporting ATPase in Ovarian Carcinoma Patients Receiving Cisplatin-Based Chemotherapy , 2004, Clinical Cancer Research.

[9]  Yves Pommier,et al.  Apoptosis defects and chemotherapy resistance: molecular interaction maps and networks , 2004, Oncogene.

[10]  Teiji Wada,et al.  Mitogen-activated protein kinases in apoptosis regulation , 2004, Oncogene.

[11]  S. Lippard,et al.  Synthesis, characterization, and cytotoxicity of a series of estrogen-tethered platinum(IV) complexes. , 2004, Chemistry & biology.

[12]  M. Bianchi,et al.  Chromatin and cell death. , 2004, Biochimica et biophysica acta.

[13]  J. Olson,et al.  p38 MAP kinase: a convergence point in cancer therapy. , 2004, Trends in molecular medicine.

[14]  T. Rudel,et al.  Requirement of caspase-mediated cleavage of c-Abl during stress-induced apoptosis , 2004, Cell Death and Differentiation.

[15]  G. Samimi,et al.  Cross-resistance to cisplatin in cells with acquired resistance to copper , 2004, Cancer Chemotherapy and Pharmacology.

[16]  S. Nicosia,et al.  Akt Phosphorylation and Stabilization of X-linked Inhibitor of Apoptosis Protein (XIAP)* , 2004, Journal of Biological Chemistry.

[17]  S. Sundar,et al.  Platinum-based chemotherapy in metastatic breast cancer: current status. , 2004, Cancer treatment reviews.

[18]  Annemieke de Vries,et al.  Activation of the p53-dependent G1 checkpoint response in mouse embryo fibroblasts depends on the specific DNA damage inducer , 2004, Oncogene.

[19]  H. Riele,et al.  Msh2 deficiency does not contribute to cisplatin resistance in mouse embryonic stem cells , 2004, Oncogene.

[20]  Jacques Robert,et al.  Molecular Determinants of the Cytotoxicity of Platinum Compounds , 2004, Cancer Research.

[21]  S. Lippard,et al.  Multiple States of Stalled T7 RNA Polymerase at DNA Lesions Generated by Platinum Anticancer Agents* , 2003, Journal of Biological Chemistry.

[22]  Andrew D Sharrocks,et al.  Transcriptional regulation by the MAP kinase signaling cascades. , 2003, Gene.

[23]  C. Menck,et al.  The eukaryotic nucleotide excision repair pathway. , 2003, Biochimie.

[24]  M. Fuertes,et al.  Pharmacological modulation of Poly(ADP-ribose) polymerase-mediated cell death: exploitation in cancer chemotherapy. , 2003, Molecular pharmacology.

[25]  Brendan M Leung,et al.  p53 is a determinant of X-linked inhibitor of apoptosis protein/Akt-mediated chemoresistance in human ovarian cancer cells. , 2003, Cancer research.

[26]  Y. Pommier,et al.  Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. , 2003, Cancer research.

[27]  T. Furuchi,et al.  Copper(II) protects yeast against the toxicity of cisplatin independently of the induction of metallothionein and the inhibition of platinum uptake. , 2003, Biochemical and biophysical research communications.

[28]  M. de Virgilio,et al.  The nuclear protein HMGB1, a new kind of chemokine? , 2003, FEBS letters.

[29]  P. Johnston,et al.  BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. , 2003, Cancer research.

[30]  J. Ford,et al.  p53 and regulation of DNA damage recognition during nucleotide excision repair. , 2003, DNA repair.

[31]  J. Boehm,et al.  p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases , 2003, Nature Reviews Drug Discovery.

[32]  K. To,et al.  Platinum‐based anticancer agents: Innovative design strategies and biological perspectives , 2003, Medicinal research reviews.

[33]  D. Reinberg,et al.  Tracking FACT and the RNA Polymerase II Elongation Complex Through Chromatin in Vivo , 2003, Science.

[34]  P. Nordmann,et al.  Association of chromatin proteins high mobility group box (HMGB) 1 and HMGB2 with mitotic chromosomes. , 2003, Molecular biology of the cell.

[35]  S. Y. Cajal,et al.  Role of the p38 MAPK pathway in cisplatin-based therapy , 2003, Oncogene.

[36]  Dong Wang,et al.  Nucleotide excision repair from site-specifically platinum-modified nucleosomes. , 2003, Biochemistry.

[37]  C. Kunz,et al.  Mutagenesis of the HMGB (high-mobility group B) protein Cmb1 (cytosine-mismatch binding 1) of Schizosaccharomyces pombe: effects on recognition of DNA mismatches and damage. , 2003, The Biochemical journal.

[38]  Stuart Thomson,et al.  MSK2 and MSK1 mediate the mitogen‐ and stress‐induced phosphorylation of histone H3 and HMG‐14 , 2003, The EMBO journal.

[39]  G. Mills,et al.  Sustained Activation of JNK/p38 MAPK Pathways in Response to Cisplatin Leads to Fas Ligand Induction and Cell Death in Ovarian Carcinoma Cells* , 2003, Journal of Biological Chemistry.

[40]  M. Oren,et al.  Decision making by p53: life, death and cancer , 2003, Cell Death and Differentiation.

[41]  Y. A. Minamishima,et al.  Modulation of p53 and p73 levels by cyclin G: implication of a negative feedback regulation , 2003, Oncogene.

[42]  M. Fuertes,et al.  Biochemical modulation of Cisplatin mechanisms of action: enhancement of antitumor activity and circumvention of drug resistance. , 2003, Chemical reviews.

[43]  J. Woodgett,et al.  Negative Regulation of Mixed Lineage Kinase 3 by Protein Kinase B/AKT Leads to Cell Survival* , 2003, The Journal of Biological Chemistry.

[44]  T. Sugiyama,et al.  Expression of copper-transporting P-type adenosine triphosphatase (ATP7B) as a chemoresistance marker in human oral squamous cell carcinoma treated with cisplatin. , 2003, Oral oncology.

[45]  S. Lippard,et al.  Cisplatin Sensitivity in Hmgb1−/− and Hmgb1+/+ Mouse Cells* , 2003, The Journal of Biological Chemistry.

[46]  K. Ogawa,et al.  Copper-transporting P-type adenosine triphosphatase (ATP7B) is expressed in human gastric carcinoma. , 2003, Cancer letters.

[47]  P. Macpherson,et al.  DNA mismatch repair and acquired cisplatin resistance in E. coli and human ovarian carcinoma cells. , 2003, DNA repair.

[48]  G. Längst,et al.  The DNA chaperone HMGB1 facilitates ACF/CHRAC‐dependent nucleosome sliding , 2002, The EMBO journal.

[49]  P. Hanawalt.  Subpathways of nucleotide excision repair and their regulation , 2002, Oncogene.

[50]  Anne M. Galea,et al.  The interaction of cisplatin and analogues with DNA in reconstituted chromatin. , 2002, Biochimica et biophysica acta.

[51]  Myriam Rochdi,et al.  Acquisition of resistance to cisplatin is accompanied by changes in the cellular pharmacology of copper. , 2002, Cancer research.

[52]  K. Ogawa,et al.  Copper‐transporting P‐type adenosine triphosphatase (ATP7B) as a cisplatin based chemoresistance marker in ovarian carcinoma: Comparative analysis with expression of MDR1, MRP1, MRP2, LRP and BCRP , 2002, International journal of cancer.

[53]  S. Y. Cajal,et al.  Modulation of PI3K/Akt pathway by E1a mediates sensitivity to cisplatin , 2002, Oncogene.

[54]  I. Herskowitz,et al.  Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[55]  E. Quoix,et al.  Platinum drugs in the treatment of non-small-cell lung cancer , 2002, British Journal of Cancer.

[56]  M. Mason,et al.  Treatment of testicular germ-cell cancer: a cochrane evidence-based systematic review. , 2002, Cancer treatment reviews.

[57]  M. Bustin.  At the Crossroads of Necrosis and Apoptosis: Signaling to Multiple Cellular Targets by HMGB1 , 2002, Science's STKE.

[58]  J. Ford,et al.  p53 and DNA damage-inducible expression of the xeroderma pigmentosum group C gene , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[59]  P. Bunn.  Chemotherapy for advanced non-small-cell lung cancer: who, what, when, why? , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  Y. Pommier,et al.  Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. , 2002, Cancer research.

[61]  L. Heasley,et al.  Regulation of platinum-compound cytotoxicity by the c-Jun N-terminal kinase and c-Jun signaling pathway in small-cell lung cancer cells. , 2002, Molecular pharmacology.

[62]  P. Bunn.  Treatment of advanced non-small-cell lung cancer with two-drug combinations. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  S. Lippard,et al.  Testis-specific HMG-domain protein alters the responses of cells to cisplatin. , 2002, Journal of inorganic biochemistry.

[64]  J. Ford,et al.  BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair , 2002, Nature Genetics.

[65]  P. Hanawalt,et al.  Ultraviolet-sensitive syndrome cells are defective in transcription-coupled repair of cyclobutane pyrimidine dimers. , 2002, DNA repair.

[66]  T. Misteli,et al.  Release of chromatin protein HMGB1 by necrotic cells triggers inflammation , 2002, Nature.

[67]  R. Schnellmann,et al.  Cisplatin-induced renal cell apoptosis: caspase 3-dependent and -independent pathways. , 2002, The Journal of pharmacology and experimental therapeutics.

[68]  K. Yeh,et al.  Increase of the resistance of human cervical carcinoma cells to cisplatin by inhibition of the MEK to ERK signaling pathway partly via enhancement of anticancer drug-induced NF kappa B activation. , 2002, Biochemical pharmacology.

[69]  P. Swanson.  Fine Structure and Activity of Discrete RAG-HMG Complexes on V(D)J Recombination Signals , 2002, Molecular and Cellular Biology.

[70]  J. Kigawa,et al.  Effect of p53 gene transfer and cisplatin in a peritonitis carcinomatosa model with p53-deficient ovarian cancer cells. , 2002, Gynecologic oncology.

[71]  J. Gutkind,et al.  Regulation of p73 by c-Abl through the p38 MAP kinase pathway , 2002, Oncogene.

[72]  S. Amundson,et al.  Implication of p53 in base excision DNA repair: in vivo evidence , 2002, Oncogene.

[73]  M. Marinus,et al.  MutS Preferentially Recognizes Cisplatin- over Oxaliplatin-modified DNA* , 2002, The Journal of Biological Chemistry.

[74]  W. El-Deiry,et al.  BRCA1 Transcriptionally Regulates Damaged DNA Binding Protein (DDB2) In the DNA Repair Response Following UV-Irradiation , 2002, Cancer biology & therapy.

[75]  A. Bellacosa.  Functional interactions and signaling properties of mammalian DNA mismatch repair proteins , 2001, Cell Death and Differentiation.

[76]  S. Benchimol.  p53-dependent pathways of apoptosis , 2001, Cell Death and Differentiation.

[77]  Miguel Martín,et al.  Platinum compounds in the treatment of advanced breast cancer. , 2001, Clinical breast cancer.

[78]  A. Rodger,et al.  Estrogen-derived steroidal metal complexes: agents for cellular delivery of metal centers to estrogen receptor-positive cells. , 2001, Inorganic chemistry.

[79]  D. Reinberg,et al.  Interaction of FACT, SSRP1, and the High Mobility Group (HMG) Domain of SSRP1 with DNA Damaged by the Anticancer Drug Cisplatin* , 2001, The Journal of Biological Chemistry.

[80]  J. Essigmann,et al.  Recognition of cisplatin adducts by cellular proteins. , 2001, Mutation research.

[81]  O. Sansom,et al.  Msh-2 suppresses in vivo mutation in a gene dose and lesion dependent manner , 2001, Oncogene.

[82]  Z. Herceg,et al.  Functions of poly(ADP-ribose) polymerase (PARP) in DNA repair, genomic integrity and cell death. , 2001, Mutation research.

[83]  José Perez,et al.  Is cisplatin-induced cell death always produced by apoptosis? , 2001, Molecular pharmacology.

[84]  Y Iwamoto,et al.  Interaction with p53 Enhances Binding of Cisplatin-modified DNA by High Mobility Group 1 Protein* , 2001, The Journal of Biological Chemistry.

[85]  G. Mills,et al.  XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells. , 2001, Cancer research.

[86]  H. Takano,et al.  Transcriptional activation of the human HMG1 gene in cisplatin-resistant human cancer cells. , 2001, Cancer research.

[87]  Xuan Sun,et al.  Akt Phosphorylates and Negatively Regulates Apoptosis Signal-Regulating Kinase 1 , 2001, Molecular and Cellular Biology.

[88]  J. Hansson,et al.  The MEK1 inhibitor PD98059 sensitizes C8161 melanoma cells to cisplatin-induced apoptosis , 2001, Melanoma research.

[89]  N. Holbrook,et al.  Requirement for ERK Activation in Cisplatin-induced Apoptosis* , 2000, The Journal of Biological Chemistry.

[90]  E. Yazlovitskaya,et al.  Cisplatin‐induced response of c‐jun N‐terminal kinase 1 and extracellular signal‐regulated protein kinases 1 and 2 in a series of cisplatin‐resistant ovarian carcinoma cell lines , 2000, Molecular carcinogenesis.

[91]  J. Darbon,et al.  Cisplatin and UV radiation induce activation of the stress-activated protein kinase p38gamma in human melanoma cells. , 2000, Biochemical and biophysical research communications.

[92]  E. E. Wilkes,et al.  cis- and trans-diamminedichloroplatinum(II) interstrand cross-linking of a defined sequence nucleosomal core particle. , 2000, Biochemistry.

[93]  Jean Y. J. Wang.  Regulation of cell death by the Abl tyrosine kinase , 2000, Oncogene.

[94]  E. Yazlovitskaya,et al.  Effect of Extracellular Signal-regulated Kinase on p53 Accumulation in Response to Cisplatin* , 2000, The Journal of Biological Chemistry.

[95]  W. Brownell,et al.  Essential role of BETA2/NeuroD1 in development of the vestibular and auditory systems. , 2000, Genes & development.

[96]  Adam P. Silverman,et al.  High-throughput synthesis and screening of platinum drug candidates , 2000, JBIC Journal of Biological Inorganic Chemistry.

[97]  R. Perona,et al.  CL100/MKP-1 modulates JNK activation and apoptosis in response to cisplatin , 2000, Oncogene.

[98]  R. Davis,et al.  Signal Transduction by the JNK Group of MAP Kinases , 2000, Cell.

[99]  S. Elledge,et al.  Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[100]  John Calvin Reed,et al.  Caspase-3 is essential for procaspase-9 processing and cisplatin-induced apoptosis of MCF-7 breast cancer cells. , 2000, Cancer research.

[101]  J. Perez,et al.  Current status of the development of trans-platinum antitumor drugs. , 2000, Critical reviews in oncology/hematology.

[102]  Zhi-Min Yuan,et al.  Activation of MEK Kinase 1 by the c-Abl Protein Tyrosine Kinase in Response to DNA Damage , 2000, Molecular and Cellular Biology.

[103]  G. Hunninghake,et al.  A constitutive active MEK --> ERK pathway negatively regulates NF-kappa B-dependent gene expression by modulating TATA-binding protein phosphorylation. , 2000, The Journal of biological chemistry.

[104]  G. Aquilina,et al.  Spontaneous development of drug resistance: mismatch repair and p53 defects in resistance to cisplatin in human tumor cells , 2000, Oncogene.

[105]  M. Gatei,et al.  Role for ATM in DNA damage-induced phosphorylation of BRCA1. , 2000, Cancer research.

[106]  S. Elledge,et al.  Chk1 is an essential kinase that is regulated by Atr and required for the G(2)/M DNA damage checkpoint. , 2000, Genes & development.

[107]  S. Lippard,et al.  Steroid hormones induce HMG1 overexpression and sensitize breast cancer cells to cisplatin and carboplatin. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[108]  P. Hanawalt,et al.  p53-Mediated DNA Repair Responses to UV Radiation: Studies of Mouse Cells Lacking p53, p21, and/orgadd45 Genes , 2000, Molecular and Cellular Biology.

[109]  F. J. Geske,et al.  DNA repair is activated in early stages of p53-induced apoptosis , 2000, Cell Death and Differentiation.

[110]  D. Alberts,et al.  Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[111]  M. Walton,et al.  Effect of p53 status on sensitivity to platinum complexes in a human ovarian cancer cell line. , 2000, Molecular pharmacology.

[112]  M. Mutoh,et al.  Copper-transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance. , 2000, Cancer research.

[113]  R Pasqualini,et al.  Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. , 2000, Cancer research.

[114]  A. Tomkinson,et al.  DNA damage-induced cell cycle checkpoints and DNA strand break repair in development and tumorigenesis , 1999, Oncogene.

[115]  S. Goff,et al.  c-Abl-induced apoptosis, but not cell cycle arrest, requires mitogen-activated protein kinase kinase 6 activation. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[116]  S. R. Datta,et al.  Cellular survival: a play in three Akts. , 1999, Genes & development.

[117]  J. Bertino,et al.  Modulation of cisplatinum cytotoxicity by p53: effect of p53-mediated apoptosis and DNA repair. , 1999, Molecular pharmacology.

[118]  D. Mercola,et al.  Inhibition of Extracellular Signal-regulated Protein Kinase or c-Jun N-terminal Protein Kinase Cascade, Differentially Activated by Cisplatin, Sensitizes Human Ovarian Cancer Cell Line* , 1999, The Journal of Biological Chemistry.

[119]  Vassilis Aidinis,et al.  The RAG1 Homeodomain Recruits HMG1 and HMG2 To Facilitate Recombination Signal Sequence Binding and To Enhance the Intrinsic DNA-Bending Activity of RAG1-RAG2 , 1999, Molecular and Cellular Biology.

[120]  P. Beale,et al.  Mini-review: discovery and development of platinum complexes designed to circumvent cisplatin resistance. , 1999, Journal of inorganic biochemistry.

[121]  M. J. Barratt,et al.  The nucleosomal response associated with immediate‐early gene induction is mediated via alternative MAP kinase cascades: MSK1 as a potential histone H3/HMG‐14 kinase , 1999, The EMBO journal.

[122]  J. Turchi,et al.  Effect of DNA polymerases and high mobility group protein 1 on the carrier ligand specificity for translesion synthesis past platinum-DNA adducts. , 1999, Biochemistry.

[123]  C. Giandomenico,et al.  Current status of platinum-based antitumor drugs. , 1999, Chemical reviews.

[124]  S. Lippard,et al.  Structure, Recognition, and Processing of Cisplatin-DNA Adducts. , 1999, Chemical reviews.

[125]  B. McKay,et al.  Potential roles for p53 in nucleotide excision repair. , 1999, Carcinogenesis.

[126]  G. Orphanides,et al.  The chromatin-specific transcription elongation factor FACT comprises human SPT16 and SSRP1 proteins , 1999, Nature.

[127]  J. Turchi,et al.  Cisplatin-induced Apoptosis Proceeds by Caspase-3-dependent and -independent Pathways in Cisplatin-resistant and -sensitive Human Ovarian Cancer Cell Lines Proteolytic Degradation of Procaspase-3 Was Observed in Both the Cp70 and C30 Cells following Ic 50 Cisplatin Treatment, Whereas No Pro- Teolyze , 2022 .

[128]  Jijie Gu,et al.  p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage , 1999, Nature.

[129]  Antonio Costanzo,et al.  The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage , 1999, Nature.

[130]  Reuven Agami,et al.  Interaction of c-Abl and p73α and their collaboration to induce apoptosis , 1999, Nature.

[131]  R. Perona,et al.  Lack of c‐Jun activity increases survival to cisplatin , 1999, FEBS letters.

[132]  D. Keppler,et al.  Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. , 1999, Molecular pharmacology.

[133]  E. Yazlovitskaya,et al.  Cisplatin-induced activation of mitogen-activated protein kinases in ovarian carcinoma cells: inhibition of extracellular signal-regulated kinase activity increases sensitivity to cisplatin. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[134]  G. Strathdee,et al.  A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer , 1999, Oncogene.

[135]  D. Winton,et al.  Msh2 status modulates both apoptosis and mutation frequency in the murine small intestine. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[136]  M. Oren,et al.  c-Abl Neutralizes the Inhibitory Effect of Mdm2 on p53* , 1999, The Journal of Biological Chemistry.

[137]  R. Wood,et al.  Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours , 1999, Current Biology.

[138]  P. Hanawalt,et al.  Expression of the p48 xeroderma pigmentosum gene is p53-dependent and is involved in global genomic repair. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[139]  P. Russell,et al.  Nuclear localization of Cdc25 is regulated by DNA damage and a 14-3-3 protein , 1999, Nature.

[140]  R. Weichselbaum,et al.  Determination of cell fate by c-Abl activation in the response to DNA damage , 1998, Oncogene.

[141]  S. Elledge,et al.  Linkage of ATM to cell cycle regulation by the Chk2 protein kinase. , 1998, Science.

[142]  Y. Minagawa,et al.  A newly developed adenovirus-mediated transfer of a wild-type p53 gene increases sensitivity to cis-diamminedichloroplatinum (II) in p53-deleted ovarian cancer cells. , 1998, European journal of cancer.

[143]  D. Lebwohl,et al.  Clinical development of platinum complexes in cancer therapy: an historical perspective and an update. , 1998, European journal of cancer.

[144]  K. Roemer,et al.  c-Abl tyrosine kinase can mediate tumor cell apoptosis independently of the Rb and p53 tumor suppressors , 1998, Oncogene.

[145]  P. J. van der Spek,et al.  Xeroderma pigmentosum group C protein complex is the initiator of global genome nucleotide excision repair. , 1998, Molecular cell.

[146]  E. Alnemri,et al.  Abrogation of Mitochondrial Cytochrome c Release and Caspase-3 Activation in Acquired Multidrug Resistance* , 1998, The Journal of Biological Chemistry.

[147]  S. Srinivasula,et al.  Autoactivation of procaspase-9 by Apaf-1-mediated oligomerization. , 1998, Molecular cell.

[148]  T. Jacks,et al.  p53-Dependent and -independent responses to cisplatin in mouse testicular teratocarcinoma cells. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[149]  S. Fulda,et al.  Chemosensitivity of solid tumor cells in vitro is related to activation of the CD95 system , 1998, International journal of cancer.

[150]  A. Kraft,et al.  Conditional expression of mitogen-activated protein kinase phosphatase-1, MKP-1, is cytoprotective against UV-induced apoptosis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[151]  E. Venkatraman,et al.  BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). , 1998, Cancer research.

[152]  C. Prives,et al.  High mobility group protein-1 (HMG-1) is a unique activator of p53. , 1998, Genes & development.

[153]  R. Perona,et al.  Cisplatin induces a persistent activation of JNK that is related to cell death , 1998, Oncogene.

[154]  E. Ruoslahti,et al.  Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. , 1998, Science.

[155]  T. Uchiumi,et al.  A canalicular multispecific organic anion transporter (cMOAT) antisense cDNA enhances drug sensitivity in human hepatic cancer cells. , 1997, Cancer research.

[156]  S. Srinivasula,et al.  Cytochrome c and dATP-Dependent Formation of Apaf-1/Caspase-9 Complex Initiates an Apoptotic Protease Cascade , 1997, Cell.

[157]  S. Aebi,et al.  Loss of DNA mismatch repair: effects on the rate of mutation to drug resistance. , 1997, Journal of the National Cancer Institute.

[158]  C. Peng,et al.  Mitotic and G2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216. , 1997, Science.

[159]  N. Rhind,et al.  Cdc25 mitotic inducer targeted by chk1 DNA damage checkpoint kinase. , 1997, Science.

[160]  S. Elledge,et al.  Conservation of the Chk1 checkpoint pathway in mammals: linkage of DNA damage to Cdk regulation through Cdc25. , 1997, Science.

[161]  M. Kool,et al.  Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. , 1997, Cancer research.

[162]  S. Aebi,et al.  Differential induction of c-Jun NH2-terminal kinase and c-Abl kinase in DNA mismatch repair-proficient and -deficient cells exposed to cisplatin. , 1997, Cancer research.

[163]  O. Potapova,et al.  The Jun Kinase/Stress-activated Protein Kinase Pathway Functions to Regulate DNA Repair and Inhibition of the Pathway Sensitizes Tumor Cells to Cisplatin* , 1997, The Journal of Biological Chemistry.

[164]  D. V. van Gent,et al.  Stimulation of V(D)J cleavage by high mobility group proteins , 1997, The EMBO journal.

[165]  K. Paull,et al.  Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. , 1996, Biochemical pharmacology.

[166]  R. Davis,et al.  The role of c-Jun N-terminal kinase (JNK) in apoptosis induced by ultraviolet C and gamma radiation. Duration of JNK activation may determine cell death and proliferation. , 1996, The Journal of biological chemistry.

[167]  P. O'Connor,et al.  Antisense GADD45 expression results in decreased DNA repair and sensitizes cells to u.v.-irradiation or cisplatin. , 1996, Oncogene.

[168]  P. Johnston,et al.  The cellular interaction of 5-fluorouracil and cisplatin in a human colon carcinoma cell line. , 1996, European journal of cancer.

[169]  R. Weichselbaum,et al.  Activation of p38 Mitogen-activated Protein Kinase by c-Abl-dependent and -independent Mechanisms* , 1996, The Journal of Biological Chemistry.

[170]  Jean Y. J. Wang,et al.  Binding of A/T-rich DNA by Three High Mobility Group-like Domains in c-Abl Tyrosine Kinase* , 1996, The Journal of Biological Chemistry.

[171]  P. Modrich,et al.  Cisplatin and Adriamycin Resistance Are Associated with MutLα and Mismatch Repair Deficiency in an Ovarian Tumor Cell Line* , 1996, The Journal of Biological Chemistry.

[172]  D. Hanahan,et al.  Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis , 1996, Cell.

[173]  S. Lippard,et al.  Repair of cisplatin--DNA adducts by the mammalian excision nuclease. , 1996, Biochemistry.

[174]  L. Zon,et al.  The stress-activated protein kinase pathway mediates cell death following injury induced by cis-platinum, UV irradiation or heat , 1996, Current Biology.

[175]  W. Lieberthal,et al.  Mechanisms of death induced by cisplatin in proximal tubular epithelial cells: apoptosis vs. necrosis. , 1996, The American journal of physiology.

[176]  B. Teicher,et al.  Effect of DNA conformation on cisplatin adduct formation. , 1996, Biochemical pharmacology.

[177]  J C Reed,et al.  Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. , 1996, Cancer research.

[178]  S. Lippard,et al.  The HMG-domain protein Ixr1 blocks excision repair of cisplatin-DNA adducts in yeast. , 1996, Mutation research.

[179]  M. Tsao,et al.  Elevated DNA repair capacity is associated with intrinsic resistance of lung cancer to chemotherapy. , 1995, Cancer research.

[180]  J C Reed,et al.  The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. , 1995, Oncogene.

[181]  P. Hanawalt,et al.  Li-Fraumeni syndrome fibroblasts homozygous for p53 mutations are deficient in global DNA repair but exhibit normal transcription-coupled repair and enhanced UV resistance. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[182]  M. Kuroda,et al.  Sensitivity of anticancer drugs in NIH3T3' cells transfected with oncogenes accompanied by pSV2neo vector. , 1995, Anticancer Research.

[183]  R. Weichselbaum,et al.  Activation of the c-Abl tyrosine kinase in the stress response to DMA-damaging agents , 1995, Nature.

[184]  Andrius Kazlauskas,et al.  The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase , 1995, Cell.

[185]  J. Mymryk,et al.  Cisplatin inhibits chromatin remodeling, transcription factor binding, and transcription from the mouse mammary tumor virus promoter in vivo. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[186]  C. Giandomenico,et al.  Carboxylation of Kinetically Inert Platinum(IV) Hydroxy Complexes. An Entr.acte.ee into Orally Active Platinum(IV) Antitumor Agents. , 1995, Inorganic chemistry.

[187]  S. Lippard,et al.  HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[188]  J. Yu,et al.  Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. , 1994, The Journal of clinical investigation.

[189]  W. Kaufmann,et al.  Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines. , 1994, Cancer research.

[190]  E. Winchester,et al.  Inhibition of DNA replication factor RPA by p53 , 1993, Nature.

[191]  S. Lippard,et al.  Ixr1, a yeast protein that binds to platinated DNA and confers sensitivity to cisplatin. , 1993, Science.

[192]  Xiaohua Wu,et al.  Nucleotide-excision repair of DNA in cell-free extracts of the yeast Saccharomyces cerevisiae. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[193]  D. Talbot,et al.  Cisplatin and its analogues in the treatment of advanced breast cancer: a review. , 1992, British Journal of Cancer.

[194]  D. Housman,et al.  Isolation and characterization of human cDNA clones encoding a high mobility group box protein that recognizes structural distortions to DNA caused by binding of the anticancer agent cisplatin. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[195]  S. Howell,et al.  Modulation of cis‐diamminedichloroplatinum(II) accumulation and sensitivity by forskolin and 3‐isobutyl‐1‐methylxanthine in sensitive and resistant human ovarian carcinoma cells , 1991, International journal of cancer.

[196]  W. Scovell,et al.  cis-diamminedichloroplatinum (II) modified chromatin and nucleosomal core particle. , 1991, Biochimica et biophysica acta.

[197]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[198]  N. Saijo,et al.  Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin. , 1991, Cancer research.

[199]  W. Scovell,et al.  cis-Diamminedichloroplatinum (II) modified chromatin and nucleosomal core particle probed with DNase I. , 1991, Biochimica et biophysica acta.

[200]  M. Dobrota,et al.  Kinetics and mechanism of uptake of platinum-based pharmaceuticals by the rat small intestine. , 1990, Biochemical pharmacology.

[201]  R. Ozols,et al.  Effect of glutathione on DNA repair in cisplatin-resistant human ovarian cancer cell lines. , 1989, Journal of the National Cancer Institute.

[202]  R. Ozols,et al.  Enhanced DNA repair and resistance to cisplatin in human ovarian cancer. , 1988, Biochemical pharmacology.

[203]  C. Sorenson,et al.  Influence of cis-diamminedichloroplatinum(II) on DNA synthesis and cell cycle progression in excision repair proficient and deficient Chinese hamster ovary cells. , 1988, Cancer research.

[204]  P. Hanawalt,et al.  Selective removal of transcription-blocking DNA damage from the transcribed strand of the mammalian DHFR gene , 1987, Cell.

[205]  R. Hromas,et al.  Decreased cisplatin uptake by resistant L1210 leukemia cells. , 1987, Cancer letters.

[206]  A. Eastman,et al.  Multiple mechanisms of resistance to cis-diamminedichloroplatinum(II) in murine leukemia L1210 cells. , 1987, Cancer research.

[207]  A. Eastman.  Cross-linking of glutathione to DNA by cancer chemotherapeutic platinum coordination complexes. , 1987, Chemico-biological interactions.

[208]  D. Priest,et al.  Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[209]  M. Foka,et al.  Interaction of cis-diamminedichloroplatinum (II) to chromatin. Specificity of the drug distribution. , 1986, Biochemical pharmacology.

[210]  S. Lippard,et al.  In vivo effects of cis- and trans-diamminedichloroplatinum(II) on SV40 chromosomes: differential repair, DNA-protein cross-linking, and inhibition of replication. , 1985, Biochemistry.

[211]  K. Harrap.  Preclinical studies identifying carboplatin as a viable cisplatin alternative. , 1985, Cancer treatment reviews.

[212]  M. Winker,et al.  Augmentation of adriamycin, melphalan, and cisplatin cytotoxicity in drug-resistant and -sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion. , 1985, Biochemical pharmacology.

[213]  P. Hanawalt,et al.  DNA repair in an active gene: Removal of pyrimidine dimers from the DHFR gene of CHO cells is much more efficient than in the genome overall , 1985, Cell.

[214]  W. Hong,et al.  Chemotherapy in head and neck cancer. , 1983, The New England journal of medicine.

[215]  S. Lippard,et al.  Binding of cis- and trans-dichlorodiammineplatinum(II) to the nucleosome core. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[216]  S. Chaney,et al.  Recognition and processing of cisplatin- and oxaliplatin-DNA adducts. , 2005, Critical reviews in oncology/hematology.

[217]  M. Fukushima,et al.  Metabolic basis of the synergistic antitumor activities of 5-fluorouracil and cisplatin in rodent tumor models in vivo , 2004, Cancer Chemotherapy and Pharmacology.

[218]  Kaori Sasai,et al.  Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53 , 2004, Nature Genetics.

[219]  S. Lippard,et al.  Cisplatin sensitivity in Hmbg1-/- and Hmbg1+/+ mouse cells. , 2003, The Journal of biological chemistry.

[220]  J. Błasiak,et al.  Recognition and repair of DNA-cisplatin adducts. , 2002, Acta biochimica Polonica.

[221]  E. Raymond,et al.  Cellular and molecular pharmacology of oxaliplatin. , 2002, Molecular cancer therapeutics.

[222]  Y. Shaul.  c-Abl: activation and nuclear targets , 2000, Cell Death and Differentiation.

[223]  Y. Hamada,et al.  Cisplatin (CDDP) specifically induces apoptosis via sequential activation of caspase-8, -3 and -6 in osteosarcoma , 2000, Cancer Chemotherapy and Pharmacology.

[224]  M. Dietel,et al.  Involvement of the DNA mismatch repair system in antineoplastic drug resistance , 1999, Journal of Cancer Research and Clinical Oncology.

[225]  R. Agami,et al.  Interaction of c-Abl and p73alpha and their collaboration to induce apoptosis. , 1999, Nature.

[226]  M. Waring,et al.  The DNA-binding domain of human c-Abl tyrosine kinase promotes the interaction of a HMG chromosomal protein with DNA. , 1999, Nucleic acids research.

[227]  M. Evans,et al.  p53 modulation of TFIIH–associated nucleotide excision repair activity , 1995, Nature Genetics.

[228]  T. Tashiro,et al.  Antitumor activity of a new platinum complex, oxalato (trans-l-1,2-diaminocyclohexane)platinum (II): new experimental data. , 1989, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[229]  Y. Lu,et al.  Mechanisms for cisplatin-FUra synergism and cisplatin resistance in human ovarian carcinoma cells both in vitro and in vivo. , 1988, Advances in experimental medicine and biology.

[230]  H. Schultz.  [Cancer of the testis]. , 1980, Ugeskrift for laeger.